anti-CD123 CAR T-cell therapy (INSERM/Invectys)

N/A

Report date: 2025/03/14 16:48:35

Base Information

Drug Nameanti-CD123 CAR T-cell therapy (INSERM/Invectys)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionInterleukin-3 receptor subunit alpha modulators
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInstitut National De La Sante Et De La Recherche Medicale
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Sante Et De La Recherche MedicaleInvectys SAS
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A